Robbie Leinart, APRN
Adult Health · Knoxville, TNNPI 1770617011
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,593 of the $47,849 with a category attached, or 72.3%. 30 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 46.8% of the total. Among adult health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 734 payments — averaging $65.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$22K
- AbbVie$19K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$905
- Nestle Healthcare Nutrition Inc.$451
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$34,59372%
- Travel & lodging$9432%
- Food & beverage$12,15025%
- Education$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 86 | $22,375 |
| AbbVie | 240 | $18,587 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 133 | $1,865 |
| Takeda Pharmaceuticals U.S.A., Inc. | 77 | $1,333 |
| Johnson & Johnson | 45 | $905 |
| Nestle Healthcare Nutrition Inc. | 31 | $451 |
| Ardelyx, Inc. | 16 | $291 |
| Merck | 13 | $271 |
| Intercept Pharmaceuticals, Inc. | 10 | $218 |
| Gilead | 11 | $215 |
| QOL Medical, LLC | 8 | $156 |
| Regeneron Healthcare Solutions, Inc. | 6 | $143 |
| Ironwood Pharmaceuticals, Inc | 8 | $123 |
| Sanofi | 6 | $116 |
| Pfizer | 6 | $110 |
| Ferring Pharmaceuticals Inc. | 6 | $91 |
| Daiichi Sankyo Inc. | 4 | $82 |
| Intra-sana Laboratories | 2 | $69 |
| Vivus LLC | 4 | $63 |
| Bristol Myers Squibb | 3 | $59 |
| Redhill Biopharma Inc. | 4 | $58 |
| Lilly USA, LLC | 3 | $52 |
| Madrigal Pharmaceuticals | 2 | $45 |
| Boehringer Ingelheim | 2 | $40 |
| Aimmune Therapeutics, Inc. | 2 | $39 |
| Braintree Laboratories, Inc. | 2 | $32 |
| Amgen | 1 | $19 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,849 in reported general payments places this provider in the 95th percentile of 352 adult health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 39 | $127,639 |
| ZenpepLipase/Protease/Amylase | 11 | $114,016 |
| Humira(Cf) PenAdalimumab | 12 | $80,275 |
| XifaxanRifaximin | 14 | $38,373 |
| LinzessLinaclotide | 32 | $23,061 |
| Colestipol Hcl | 118 | $16,558 |
| Mesalamine | 14 | $13,266 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 30 | $5,087 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 61 | $4,191 |
| Budesonide DrBudesonide | 16 | $4,183 |
| Mesalamine ErMesalamine | 18 | $3,479 |
| Famotidine | 216 | $3,455 |
| Pantoprazole Sodium | 242 | $2,329 |
| Balsalazide Disodium | 14 | $1,901 |
| Ondansetron Hcl | 56 | $1,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $18,587 | $150,69971 claims |
| Aimmune Therapeutics, Inc.Zenpep | $39 | $114,01611 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,865 | $38,37314 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $91 | $5,08730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 352 adult health providers in Tennessee.
Other adult health in Knoxville
- Jacquelynne PrinceKnoxville$8K
- Sara JonesKnoxville$8K
- Kristy BowersKnoxville$7K
- Mary HammondsKnoxville$5K
- Tina PaulKnoxville$4K
- Sherry CoffieldKnoxville$4K
- Lauren MonroeKnoxville$4K
- Brenda BaxterNashville$246K
- Artangela HenryMemphis$74K
- Luisa LealNashville$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.